December 29, 2017

Notable Analyst Upgrades and Downgrades for Week of December 25, 2017



Upgrades:


AstraZeneca (NYSE:AZN) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research report issued on Friday. Several other equities analysts also recently weighed in on the stock. Natixis raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Leerink Swann boosted their target price on shares of AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Argus reissued a “buy” rating and issued a $35.00 target price on shares of AstraZeneca in a report on Friday, September 1st. Finally, BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, October 31st. Four analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. AstraZeneca currently has a consensus rating of “Hold” and a consensus price target of $34.20. Read more …

Novo Nordisk A/S (NYSE:NVO) was upgraded by research analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a note issued to investors on Friday. NVO has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Bank of America raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, December 6th. BNP Paribas downgraded shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $55.00. Read more …


Downgrades:


Riocan Real Estate (OTCMKTS:RIOCF) was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Friday, The Fly reports. Shares of Riocan Real Estate (OTCMKTS RIOCF) opened at $19.62 on Friday. Read more …






In case you interested of stock analysis of other bloggers, click on link below:


Analysis Collection


No comments:

Post a Comment